News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
oryzon building
ORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount Sinai
Goal is to explore effects of LSD1 inhibition on animal models of autism in Shank3 deficient…
Partners - Oryzon Genomics
Gema Malet, PhD
Our researcher in oncology, Gema Malet, receives a Marie Skłodowska-Curie research grant
In 2020, biologist Gema Malet Engra joined the biotechnology company Laminar Pharmaceuticals after…
Partners - Laminar Pharma
logo oryzon
ORYZON enrolls first patient in PORTICO
PORTICO is a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder …
Partners - Oryzon Genomics
IUL, lateral flow reader
IUL launches iPeak+, the new lateral flow reader for rapid tests
IUL SA launches iPeak+, a new colorimetric off-the-shelf lateral flow reader designed to hold large…
logo oyrzon
ORYZON publishes vafidemstat first-in-human clinical trial manuscript in CNS Drugs journal
Vafidemstat displayed good safety and tolerability in healthy young and elderly volunteers
Partners - Oryzon Genomics
logo oryzon
ORYZON to participate in upcoming virtual international conferences in March and April
The company will attend to BIO-Europe Spring 2021, Kempen Life Sciences Conference and the…
logo oryzon
ORYZON announces successful pre-IND meeting with FDA for the clinical development of vafidemstat in Borderline Personality Disorder
Oryzon will consequently proceed to file an IND application  PORTICO will be developed in…
test biolan
BIOLAN has launched its rapid serological test for the detection of antibodies against COVID-19 with a guaranteed industrial production capacity
The Basque SME located in Zamudio has invested heavily to equip itself with the equipment that will…
logo oryzon
ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the virtual AD/PD-2021 conference